Aloeemodin
Catalog No: CFN98749
Aloeemodin is an interferon-inducing agent with IC50 of about 1 μg/mL for JEV and of about 0.33 μg/mL for EV71. Aloeemodin has antitumor, neuroprotective, and anti-fibrosis effects, it inhibited β-amyloid aggregation, downregulated the expression of Smad2 mRNA and TGF-β1,TIMP1,and type Ⅰ and Ⅲ collagen proteins,and upregulated the expression of Smad7 mRNA.
Isoquercitrin
Catalog No: CFN98753
Isoquercitrin has anti-tumoral, antihypertensive, anti-osteoporosis, anti-allergy,
anti-inflammatory, and antiasthmatic activities, it also may be as a potential therapeutic agent against neurodegeneration in Parkinson's disease. Isoquercitrin is an inhibitor of Wnt/β-catenin that acts downstream of the β-catenin nuclear translocation; it is also a potential stimulator of bone mineralization used for prophylaxis of osteoporotic disorders. Isoquercitrin inhibited carbachol and leukotriene D4 -induced contraction in guinea-pig airways, and it induced hypotension in rats is an event dependent on the inhibition of angiotensin II generation by angiotensin converting enzyme (ACE).
Kaempferitrin
Catalog No: CFN98756
Kaempferitrin exerts immunostimulatory, antidepressant-like , antiosteoporotic , cytotoxic and antitumor effects, the general mechanisms include cell cycle arrest in G1 phase and apoptosis via intrinsic pathway in a caspase dependent pathway. Kaempferitrin is an acute lowering effect on blood glucose in diabetic rats and to stimulate the glucose uptake percentile, as efficiently as insulin in muscle from normal rats.
Afzelin
Catalog No: CFN98757
Afzelin has several cellular activities such as DNA-protective, antibacterial, antioxidant, and anti-inflammatory as well as UV-absorbing activity and may protect human skin from UVB-induced damage by a combination of UV-absorbing and cellular activities.
Afzelin has potenial anti-cancer activity against prostate cancer, the activity is due to inhibition of LIM domain kinase 021 expression, it can inhibit the proliferation of LNCaP and PC302cells, and block the cell cycle in the G002phase. Afzelin can attenuate asthma phenotypes is based on reduction of Th2 cytokine via inhibition of GATA-binding protein 3 transcription factor, which is the master regulator of Th2 cytokine differentiation and production.
